Kivorent News

Wednesday, November 18, 2026

Health techLooking back

August 2026: the FDA authorized Abbott's Libre Duo glucose and ketone sensor

Abbott said on August 25, 2026, that the FDA had authorized Libre Duo 10 Day, a wearable that measures both glucose and ketones, with a US launch now planned for December.

Pulse, covering wearables and health sensors
Published , 3 min read

2+minimum age for Libre Duo 10 Day, per Abbott

This is a look back at an event from . We wrote it on November 15, 2026, from the sources listed at the end.

What to know

  • Abbott announced FDA De Novo authorization for Libre Duo 10 Day, which reads glucose and ketones from one sensor, on August 25, 2026.
  • It is for people 2 and older with type 1 or type 2 diabetes who take insulin or other glucose-lowering drugs such as SGLT2 inhibitors.
  • Abbott's CEO told investors in October that the US launch is planned for December, according to Drug Delivery Business News.

Abbott said on August 25, 2026, that the US Food and Drug Administration had authorized Libre Duo 10 Day, a skin-worn sensor that measures both glucose and ketones. Abbott calls it the world's first dual glucose-ketone sensing technology. It went through the FDA's De Novo pathway after earlier receiving breakthrough device designation, according to the company's release, Pharmacy Times and U.S. Pharmacist.

The authorization came before Kivorent News began covering wearables. It matters again now because Abbott has set a date: chief executive Robert Ford told investors on the company's October 21 earnings call that the US launch is planned for December, according to Drug Delivery Business News.

What the sensor does

A standard continuous glucose monitor (CGM) reads sugar levels in the fluid just under the skin. Libre Duo adds a second reading for ketones, acids the body makes when it burns fat because it cannot use glucose. Very high ketones can signal diabetic ketoacidosis (DKA), a dangerous complication. Today most people check ketones with a finger-stick meter or a urine strip.

Abbott says glucose shows in real time while ketone tracking runs in the background, with alerts when ketones rise or reach a high level. Pharmacy Times reported that the sensor measures both every minute and sends readings to a phone. The release notes that its urgent alarms may not catch every case of glucose below 55 mg/dL or ketones above 3.0 mmol/L.

Abbott says Libre Duo is the first system to meet both the FDA's integrated CGM (iCGM) standard and a new integrated glucose-and-ketone (iCGK) standard. Pharmacy Times, citing the FDA, said six clinical studies with more than 600 participants supported the decision. None of the sources gives a numeric accuracy figure for the ketone reading.

Who it is for

The sensor is authorized for people 2 and older with type 1 or type 2 diabetes who take insulin or other glucose-lowering drugs, such as SGLT2 inhibitors. Abbott aimed it at people at higher risk of elevated ketones.

It is rated for up to 10 days of wear. In Abbott's own footnote, 84.1% of adult sensors and 68.8% of children's sensors lasted the full 10 days.

Apps and insulin pumps

Libre Duo runs on Abbott's latest Libre app in the US and feeds LibreView for clinicians and LibreLinkUp for caregivers. Abbott said it expected the sensor to work with the Beta Bionics iLet and Sequel twiist automated insulin systems by the end of 2026, with Insulet and Tandem in 2027. It also announced an exclusive tie-up with MiniMed, expected in 2027.

Abbott has not published a price. Ford said on the October call that the company has to "get the pricing aspect right," according to Drug Delivery Business News.

Coverage and competition

The launch lands as Abbott and Dexcom fight over insurance coverage. MedTech Dive reported on November 2 that some CVS Caremark and Aetna commercial customers will switch from Dexcom-exclusive to Abbott-exclusive CGM coverage in 2027, and that both companies are waiting on a Medicare decision on CGMs for people with type 2 diabetes who do not use insulin. Dexcom's own outlook is in our report on Dexcom's third-quarter results. The De Novo route is explained in what cleared, approved and De Novo mean.

Why it matters

If it works as Abbott describes, Libre Duo would let people who use insulin or SGLT2 drugs get a ketone warning from the sensor they already wear, instead of a separate finger-stick or urine test, for a risk that glucose readings alone can miss. Its December launch also gives Abbott a new product to sell just as insurers decide which CGM brand they will cover. Other companies are also widening what a CGM can be, from Huawei's Sense G1 to Oura's glucose features.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

Glucose and metabolic techFDA and health regulationWearablesDigital health and AI in care

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.